This technology is a serological assay that utilizes bead technology to simultaneously perform up to 64,000 clinical tests in a single run.
Current serological immunoassays are limited in the number of analytes and number of samples that can be simultaneously detected in a single run. There is a need for a method of large-scale, high-throughput population testing of viral exposure for improved disease monitoring and control during the COVID-19 pandemic.
This technology utilizes bead sets coated in SARS-CoV-2 proteins to detect the presence of antibodies in large sets of human serum samples. It can simultaneously process tens of thousands of biological samples in a single run. In addition, this technology has been shown to work on Luminex systems. As such, this technology can be used to inexpensively and efficiently perform antibody tests on large population cohorts for improved disease monitoring and diagnostics.
Patent Pending
IR CU20326
Licensing Contact: Sara-Ann Gusik